Source: Global Battery Metals Ltd.
  • Global Battery Metals (GBML) has submitted a drilling permit application for its Leinster Project in Ireland
  • 10 drill holes are planned to test to a depth of 200 metres
  • Significant sampling and mapping across the Knockeen Prospect was conducted throughout the second half of 2022, with the most recent assay results of 66 rock samples released by ALS Laboratories ranging up to 3.75 per cent Li2O
  • Global Battery Metals (GBML) opened trading at $0.18 per share

Global Battery Metals (GBML) has submitted a drilling permit application for its Leinster Project in Ireland.

10 drill holes are planned to test to a depth of 200 metres.

Significant sampling and mapping across the Knockeen Prospect was conducted throughout the second half of 2022, with the most recent assay results of 66 rock samples released by ALS Laboratories ranging up to 3.75 per cent Li2O.

Source: Global Battery Metals Ltd.

Alongside this work, a detailed deep overburden program interpreted geochemical results leading to the potential discovery of up to six LCT (lithium-cesium-tantalum) pegmatite dikes across the Knockeen Prospect shallow depths of between 1 metre to 7 metres below ground surface.

In this area, previous exploration by another company had unearthed a trench excavated at Knockeen Townland which uncovered in bedrock, a 1.8 metre thick spodumene-bearing pegmatite vein.

Global Battery Metals Ltd. is an international mineral exploration and development company focused on supplying the battery industry.

Global Battery Metals (GBML) opened trading at $0.18 per share.

More From The Market Online

@ the Bell: TSX hits new high then closes in the red

The TSX hit a record high on Friday, before falling into the red by market close tracking a rally in prices for metals.

This AI tech stock is growing exponentially: What you need to know

AI tech stock Metaguest.AI (CSE:METG) grows subscription sales and experience bookings by almost 10x since Q1 2023.
labratory work

PharmaTher locks in FDA-assigned goal date of abbreviated NDA

PharmaTher Holdings (CSE:PHRM) locks in its U.S. FDA-assigned goal date of abbreviated new drug application for Oct. 29, 2024.